The role of nitric oxide- and prostacyclin-independent vasodilatation in the human cutaneous microcirculation: Effect of cytochrome P450 2C9 inhibition

Clinical Physiology and Functional Imaging

Volumn 29, Issue 4, 2009, Pages 263-270

  Lenasi, Helena ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Endothelium; Endothelium dependent vasodilatation; Endothelium derived hyperpolarizing factor; Intradermal microinjection; Laser Doppler fluxmetry; Skin; Sulfaphenazole

Indexed keywords

ACETYLCHOLINE; CYTOCHROME P450 2C9; DICLOFENAC; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFAPHENAZOLE;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; MALE; MICROCIRCULATION; MICROINJECTION; NORMAL HUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SKIN BLOOD FLOW; VASODILATATION;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BLOOD FLOW VELOCITY; EPOPROSTENOL; FEMALE; HUMANS; MALE; MICROCIRCULATION; NITRIC ACID; SKIN; SKIN PHYSIOLOGICAL PHENOMENA; SULFAPHENAZOLE;

EID: 67049116265     PISSN: 14750961     EISSN: 1475097X     Source Type: Journal    
DOI: 10.1111/j.1475-097X.2009.00862.x     Document Type: Article

References (46)

1. Alvarez J, Montero M, Garcia-Sancho J. High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem (1992); 267: 11789-11793.
2. Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, Platonov M, Koshal A, Hashimoto K, Campbell WB, Falck JR, Michelakis ED. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation (2003); 107: 769-776.
3. Batenburg WW, Garrelds IM, van Kats JP, Saxena PR, Danser AH. Mediators of bradykinin-induced vasorelaxation in human coronary microarteries. Hypertension (2004); 43: 488-492.
4. Bellien J, Joannides R, Iacob M, Arnaud P, Thuillez C. Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Am J Physiol Heart Circ Physiol (2006); 290: H1347-H1352.
5. Binggeli C, Spieker LE, Corti R, Sudano I, Stojanovic V, Hayoz D, Lüscher TF, Noll G. Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients: A monitoring test of endothelial dysfunction for clinical practice? J Am Coll Cardiol (2003); 42: 71-77.
6. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci (2002); 23: 374-380.
7. Buus NH, Simonsen U, Pilegaard HK, Mulvany MJ. Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries. Br J Pharmacol (2000); 129: 184-192.
8. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res (1996); 78: 415-423.
9. Coats P, Johnston F, MacDonald J, McMurray JJ, Hillier C. Endothelium-derived hyperpolarizing factor: Identification and mechanisms of action in human subcutaneous resistance arteries. Circulation (2001); 103: 1702-1708.
10. Deja MA, Golba KS, Widenka K, Mrozek R, Biernat J, Kolowca M, Malinowski M, Woś S. Angiotensin-converting enzyme inhibitors reveal non-NO-, non-prostacycline-mediated endothelium-dependent relaxation in internal thoracic artery of hypertensive patients. Int J Cardiol (2005); 102: 455-460.
11. Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation (2004); 109: 178-183.
12. Fischer D, Landmesser U, Spiekermann S, Hilfiker-Kleiner D, Hospely M, Müller M, Busse R, Fleming I, Drexler H. Cytochrome P450 2C9 is involved in flow-dependent vasodilatation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure. Eur J Heart Fail (2007); 9: 770-775.
13. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature (1999); 401: 493-497.
14. Fleming I. Cytochrome P450 epoxygenase as EDHF synthase(s). Pharmacol Res (2004); 49: 525-533.
15. Gaubert ML, Sigaudo-Roussel D, Tartas M, Berrut G, Saumet JL, Fromy B. Endothelium-derived hyperpolarizing factor as an in vivo back-up mechanism in the cutaneous microcirculation in old mice. J Physiol (2007); 585 (Pt 2): 617-626.
16. Golster H, Hyllienmark L, Ledin T, Ludvigsson J, Sjöberg F. Impaired microvascular function related to poor metabolic control in young patients with diabetes. Clin Physiol Funct Imaging (2005); 25: 100-105.
17. Halcox JP, Narayanan S, Cramer-Joyce L, Mincemoyer R, Quyyumi AA. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am J Physiol Heart Circ Physiol (2001); 280: H2470-H2477.
18. Hamilton CA, Williams R, Pathi V, Berg G, McArthur K, McPhaden AR, Reid JL, Dominiczak AF. Pharmacological characterisation of endothelium-dependent relaxation in human radial artery: Comparison with internal thoracic artery. Cardiovasc Res (1999); 42: 214-223.
19. Hansell J, Henareh L, Agewall S, Norman M. Non-invasive assessment of endothelial function - relation between vasodilatory responses in skin microcirculation and brachial artery. Clin Physiol Funct Imaging (2004); 24: 317-322.
20. Hecker M. Endothelium-derived hyperpolarizing factor-fact or fiction? News Physiol Sci (2000); 15: 1-5.
21. Hecker M, Bara AT, Bauersachs J, Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol (1994); 481: 407-414.
22. Hillig T, Krustrup P, Fleming I, Osada T, Saltin B, Hellsten Y. Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J Physiol (2003); 546: 307-314.
23. Holowatz LA, Thompson CS, Minson CT, Kenney WL. Mechanisms of acetylcholine-mediated vasodilatation in young and aged human skin. J Physiol (2005); 563: 965-973.
24. Huang A, Sun D, Jacobson A, Carroll MA, Falck JR, Kaley G. Epoxyeicosatrienoic acids are released to mediate shear stress-dependent hyperpolarization of arteriolar smooth muscle. Circ Res (2005); 96: 376-383.
25. Inokuchi K, Hirooka Y, Shimokawa H, Sakai K, Kishi T, Ito K, Kimura Y, Takeshita A. Role of endothelium-derived hyperpolarizing factor in human forearm circulation. Hypertension (2003); 42: 919-924.
26. Jägrén C, Gazelius B, Ihrman-Sandal C, Lindblad LE, Ostergren J. Skin microvascular dilatation response to acetylcholine and sodium nitroprusside in peripheral arterial disease. Clin Physiol Funct Imaging (2002); 22: 370-374.
27. Katz SD, Krum H. Acetylcholine-mediated vasodilatation in the forearm circulation of patients with heart failure: Indirect evidence for the role of endothelium-derived hyperpolarizing factor. Am J Cardiol (2001); 87: 1089-1092.
28. Kubli S, Waeber B, Dalle-Ave A, Feihl F. Reproducibility of laser Doppler imaging of skin blood flow as a tool to assess endothelial function. J Cardiovasc Pharmacol (2000); 36: 640-648.
29. Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, Gutterman DD. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: Implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol (2006); 290: H491-H499.
30. Lenasi H, Strucl M. The effect of nitric oxide synthase and cyclooxygenase inhibition on cutaneous microvascular reactivity. Eur J Appl Physiol (2008); 103: 719-726.
31. Leslie SJ, Affolter J, Denvir MA, Webb DJ. Validation of laser Doppler flowmetry coupled with intra-dermal injection for investigating effects of vasoactive agents on the skin microcirculation in man. Eur J Clin Pharmacol (2003); 59: 99-102.
32. Luksha L, Nisell H, Kublickiene K. The mechanism of EDHF-mediated responses in subcutaneous small arteries from healthy pregnant women. Am J Physiol Regul Integr Comp Physiol (2004); 286: R1102-R1109.
33. Mancy A, Dijols S, Poli S, Guengerich P, Mansuy D. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry (1996); 35: 16205-16212.
34. McGuire JJ, Ding H, Triggle CR. Endothelium-derived relaxing factors: A focus on endothelium-derived hyperpolarizing factor(s). Can J Physiol Pharmacol (2001); 79: 443-470.
35. Miura H, Gutterman DD. Human coronary arteriolar dilation to arachidonic acid depends on cytochrome P-450 monooxygenase and Ca2+-activated K+ channels. Circ Res (1998); 83: 501-507.
36. Newton DJ, Khan F, Belch JJ. Assessment of microvascular endothelial function in human skin. Clin Sci (2001); 101: 567-572.
37. Nilsson GE. Perimeds LDV flowmeter. In: Laser-Doppler Flowmetry (ed. Sheperd, AP) (1990), pp. 57-72. Kluwer Academic, Boston, MA.
38. Opazo Saez AM, Mosel F, Nürnberger J, Rushentsova U, Gössl M, Mitchell A, Schäfers RF, Philipp T, Wenzel RR. Laser Doppler imager (LDI) scanner and intradermal injection for in vivo pharmacology in human skin microcirculation: Responses to acetylcholine, endothelin-1 and their repeatability. Br J Clin Pharmacol (2005); 59: 511-519.
39. Passauer J, Bussemaker E, Lassig G, Pistrosch F, Fauler J, Gross P, Fleming I. Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole. Clin Sci (Lond) (2003); 105: 513-518.
40. Schrage WG, Dietz NM, Eisenach JH, Joyner MJ. Agonist-dependent variablity of contributions of nitric oxide and prostaglandins in human skeletal muscle. J Appl Physiol (2005); 98: 1251-1257.
41. Taddei S, Versari D, Cipriano A, Ghiadoni L, Galetta F, Franzoni F, Magagna A, Virdis A, Salvetti A. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J Am Coll Cardiol (2006); 48: 508-515.
42. Ueda K, Goto C, Jitsuiki D, Umemura T, Nishioka K, Kimura M, Noma K, Nakagawa K, Oshima T, Yoshizumi M, Chayama K, Higashi Y. The nicorandil-induced vasodilatation in humans is inhibited by miconazole. J Cardiovasc Pharmacol (2005); 45: 290-294.
43. Urakami-Harasawa L, Shimokawa H, Nakashima M, Egashira K, Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest (1997); 100: 2793-2799.
44. Wenzel RR. Minimal invasive in vivo pharmacology: News of a new method holding promise in nephrology-related research. Nephrol Dial Transplant (1997); 12: 649-651.
45. de Wit C, Wolfle SE. "EDHF and gap junctions: Important regulators of vascular tone within the microcirculation. Curr Pharm Biotechnol (2007); 8: 11-25.
46. Yanga Q, Yima AP, He GW. The significance of endothelium-derived hyperpolarizing factor in the human circulation. Curr Vasc Pharmacol (2007); 5: 85-92.